Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2015 (fiscal third quarter of 2015; not 2014 Q3 as indicated in the request metadata). The filing was signed May 12, 2015. Palatin is a development-stage biopharmaceutical company with no product sales.
Financial results and liquidity
| Metric | Three months ended March 31, 2015 | Nine months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $0 | $12.95 million | $0 |
| Research and development expense | $7.59 million | $14.79 million | $2.15 million and $8.23 million, respectively |
| General and administrative expense | $1.13 million | $3.67 million | $1.21 million and $3.24 million, respectively |
| Net loss | $9.15 million | $5.58 million | $1.51 million and $9.61 million, respectively |
| Basic and diluted net loss per share | $0.07 | $0.05 | $0.01 and $0.09, respectively |
Nine-month operating loss was $5.51 million, compared with $11.47 million in 2014. The filing reports no gross margin; revenue consisted of collaboration/license payments, not product sales. The prior-year periods included a $1.85 million income-tax benefit from selling New Jersey net operating loss carryforwards, versus $0.53 million in the current nine-month period and none in the current quarter.
- Cash and cash equivalents: $36.73 million at March 31, 2015, up from $12.18 million at June 30, 2014.
- Cash flow: $3.89 million used in operating activities for the nine months, versus $7.69 million used in 2014. Financing provided $28.43 million, mainly from a $20 million private placement and $10 million venture loan. No investing cash flow was reported.
- Liquidity: Current assets were $38.70 million and current liabilities $5.19 million, implying working capital of about $33.51 million.
- Debt: A $10 million secured venture loan was recorded at $9.76 million net of discount. It carries interest at one-month LIBOR, subject to a 0.50% floor, plus 8.50%; interest-only payments run for 18 months, followed by monthly principal payments. The loan matures January 1, 2019 and is secured by substantially all assets other than intellectual property.
- Equity and dilution: Common shares outstanding were 42.16 million at March 31. The filing reports weighted-average shares of 134.01 million for the quarter and 116.63 million for the nine months, reflecting the accounting treatment of nominal-exercise-price warrants. It also lists 116.05 million warrant shares among outstanding dilutive securities.
Material changes versus the prior comparable periods
- Palatin recognized $12.95 million of revenue in the first nine months of fiscal 2015, entirely from Gedeon Richter; the prior-year period had no revenue. There was no revenue in the March 2015 quarter.
- R&D expense rose 253% in the quarter and 80% for the nine months, primarily reflecting the bremelanotide Phase 3 program initiated in December 2014. G&A increased 13% for the nine months, attributed mainly to accounting and other professional services.
- Nine-month net loss narrowed year over year, while the quarterly net loss widened substantially. Comparisons are affected by collaboration revenue, higher development spending, foreign-exchange losses, interest expense, and the prior-year tax benefit.
- Cash increased materially following the December 2014 financing transactions. Common shares outstanding also increased, and the private placement included substantial warrant coverage.
Outlook, management commentary, risks, and unusual items
- Management estimated the bremelanotide Phase 3 program, including regulatory filings, would cost at least $80 million. The trials were expected to take at least 15–18 months from initiation of patient dosing through database lock; the timing and outcome of any NDA filing remained conditional on trial results and FDA review.
- Management believed existing capital resources would fund currently planned operations through the quarter ending June 30, 2016, but said additional funding would be needed to complete Phase 3. Potential sources include partnerships, equity or debt financing, and other arrangements. The filing cautions that financing may not be available on acceptable terms or at all.
- Palatin expected continued losses and stated that profitability, if achieved, depended on successful development, regulatory approval, and commercialization. It reported an accumulated deficit of $279.6 million.
- The company’s primary development candidate is injectable bremelanotide for female sexual dysfunction. Other programs include PL-3994 and MC1r and MC4r candidates. AstraZeneca was evaluating its melanocortin program; Palatin disclosed that AstraZeneca had discontinued development of AZD2820 following a serious adverse event.
- Gedeon Richter agreement terms include potential milestones of up to €80 million and low double-digit royalties on licensed-territory net sales, subject to development, regulatory, and commercial success. The nine-month revenue was concentrated entirely in this agreement. Euro/U.S. dollar movements produced foreign-exchange losses of $0.13 million for the quarter and $0.28 million for the nine months.
- Key risks include clinical-trial failure or delay, regulatory and device approval, dependence on third-party contractors and manufacturers, limited recurring revenue, future financing needs, competition and uncertain reimbursement. The filing said no legal proceeding was pending and reported effective disclosure controls as of March 31, 2015.
Most important facts for investors to verify
- Reconcile the reported revenue and net-loss figures across the statements, notes, and MD&A, and confirm the timing and conditions of Gedeon Richter payments.
- Assess Phase 3 enrollment, duration, results, regulatory pathway, and the estimated $80 million-plus funding requirement against the stated cash runway through June 2016.
- Review the complete terms, collateral, interest burden, covenants, and prepayment costs of the venture loan, and any financing plans or partner negotiations.
- Quantify potential dilution and warrant-related share-count effects, including the reported weighted-average share figures and the large warrant overhang.
- Monitor AstraZeneca’s decisions on its licensed program and the status, safety, and development costs of Palatin’s other candidates.